A&M has role in saving U.S. from pathogens: A&M has role in saving U.S. from pathogens Houston Chronicle Copyright... http://t.co/Ams9fSrw
A. In June, U.S. Department of Health and Human Services Secretary (Kathleen) Sebelius announced that Texas A&M University is one of three new centers that will be receiving funding to build or renovate facilities to develop and manufacture medical countermeasures, such as vaccines and medicines used in an emergency. The center, as a public-private partnership, will enhance the nation's emergency preparedness against emerging infectious diseases, including pandemic influenza and chemical, biological, radiological and nuclear threats. A. Texas A&M created a consortium with several of the world's best pharmaceutical companies, including GlaxoSmithKline and Lonza, and some of the most innovative local companies, including Caliber Biotherapeutics, to provide a formidable team that can make vaccines quickly in a public health emergency and help companies in need to develop and manufacture their vaccines on a routine basis. A. Had the 2009 H1N1 pandemic been more severe, then we would have executed contingency plans that included medical countermeasures and other social distancing mitigation measures. A. These centers, all based in the United States, will produce and make available pandemic flu vaccines sooner than in 2009 due to newer vaccine and flexible manufacturing technologies., A. In June, U.S. Department of Health and Human Services Secretary (Kathleen) Sebelius announced that Texas A&M University is one of three new centers that will be receiving funding to build or renovate facilities to develop and manufacture medical countermeasures, such as vaccines and medicines used in an emergency. The center, as a public-private partnership, will enhance the nation's emergency preparedness against emerging infectious diseases, including pandemic influenza and chemical, biological, radiological and nuclear threats. A. Texas A&M created a consortium with several of the world's best pharmaceutical companies, including GlaxoSmithKline and Lonza, and some of the most innovative local companies, including Caliber Biotherapeutics, to provide a formidable team that can make vaccines quickly in a public health emergency and help companies in need to develop and manufacture their vaccines on a routine basis. A. Had the 2009 H1N1 pandemic been more severe, then we would have executed contingency plans that included medical countermeasures and other social distancing mitigation measures. A. These centers, all based in the United States, will produce and make available pandemic flu vaccines sooner than in 2009 due to newer vaccine and flexible manufacturing technologies.
Link -
Trackbacks